ArticlePLoS computational biology2023
BiComp-DTA: Drug-target binding affinity prediction through complementary biological-related and compression-based featurization approach.
Article in PLoS computational biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- GraESM-FuseDTA: adaptive gated multimodal fusion of graph neural networks and protein language models for robust drug-target affinity prediction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A novel method for drug-target affinity prediction by integrating predicted evolutionary information and multi-scale protein graphs.BMC biology · 2026Article
- MLDTA an Ensemble-Driven Multimodal Model with Dynamic Fusion for Drug-Target Affinity Prediction.Interdisciplinary sciences, computational life sciences · 2026Article
- Computational approach for the evaluation of sesquiterpene lactone as a modulator of cannabinoid receptor type 2 for neurodegenerative disease prophylactics.Molecular diversity · 2026Article
- DualPG-DTA: A Large Language Model-Powered Graph Neural Network Framework for Enhanced Drug-Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti-Leukemia Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- DTAP: a unified graph transformer framework for joint prediction of drug-target affinity and docking pose.Briefings in bioinformatics · 2026Article
- In silico methods for drug-target interaction prediction.Cell reports methods · 2025Review
- MultiKD-DTA: Enhancing Drug-Target Affinity Prediction Through Multiscale Feature Extraction.Interdisciplinary sciences, computational life sciences · 2025Article
- A survey on deep learning for drug-target binding prediction: models, benchmarks, evaluation, and case studies.Briefings in bioinformatics · 2025Review
- Deep Drug-Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion.ACS omega · 2025Article
- DrugForm-DTA: Towards real-world drug-target binding affinity model.Computational and structural biotechnology journal · 2025Article
- Structure-inclusive similarity based directed GNN: a method that can control information flow to predict drug-target binding affinity.Bioinformatics (Oxford, England) · 2024Article
- Leveraging multiple data types for improved compound-kinase bioactivity prediction.Nature communications · 2024Article
- LSTM-SAGDTA: Predicting Drug-target Binding Affinity with an Attention Graph Neural Network and LSTM Approach.Current pharmaceutical design · 2024Article
- Multimodal pretraining for unsupervised protein representation learning.Biology methods & protocols · 2024Article
- A comprehensive review of the recent advances on predicting drug-target affinity based on deep learning.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-target binding affinity prediction plays a key role in the early stage of drug discovery. Numerous experimental and data-driven approaches have been developed for predicting drug-target binding affinity. However, experimental methods highly rely on the limited structural-related information from drug-target pairs, domain knowledge, and time-consuming assays. On the other hand, learning-based methods have shown an acceptable prediction performance. However, most of them utilize several simple and complex types of proteins and drug compounds data, ranging from the protein sequences to the topology of a graph representation of drug compounds, employing multiple deep neural networks for encoding and feature extraction, and so, leads to the computational overheads. In this study, we propose a unified measure for protein sequence encoding, named BiComp, which provides compression-based and evolutionary-related features from the protein sequences. Specifically, we employ Normalized Compression Distance and Smith-Waterman measures for capturing complementary information from the algorithmic information theory and biological domains, respectively. We utilize the proposed measure to encode the input proteins feeding a new deep neural network-based method for drug-target binding affinity prediction, named BiComp-DTA. BiComp-DTA is evaluated utilizing four benchmark datasets for drug-target binding affinity prediction. Compared to the state-of-the-art methods, which employ complex models for protein encoding and feature extraction, BiComp-DTA provides superior efficiency in terms of accuracy, runtime, and the number of trainable parameters. The latter achievement facilitates execution of BiComp-DTA on a normal desktop computer in a fast fashion. As a comparative study, we evaluate BiComp's efficiency against its components for drug-target binding affinity prediction. The results have shown superior accuracy of BiComp due to the orthogonality and complementary nature of Smith-Waterman and Normalized Compression Distance measures for protein sequences. Such a protein sequence encoding provides efficient representation with no need for multiple sources of information, deep domain knowledge, and complex neural networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.